arrow
V

Vu H. Duong

university of maryland greenebaum comprehensive cancer center
H指数:23
被引数:1,826

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Signaling Mutations Negate the Favorable Impact of NPM1 Mutations in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With VEN/HMA

信号突变抵消了新诊断急性髓系白血病老年患者接受VEN/HMA治疗时NPM1突变的有利影响

2026-07-020
OAAI
Case Report: Pathologic complete response in a patient with simultaneous diagnoses of resectable NSCLC and myeloid neoplasm with PDGFRA rearrangement treated with concurrent neoadjuvant chemoimmunotherapy and imatinib: translating clinical trial data to real-world practice

病例报告:1例可切除非小细胞肺癌(NSCLC)和PDGFRA重排的髓系肿瘤同时诊断患者,经新辅助化疗免疫联合治疗及伊马替尼治疗后达到病理完全缓解:将临床试验数据转化为真实世界实践

2025-07-290
OA
Molecular characterization of newly diagnosed acute myeloid leukemia patients aged 60 years or older: a report from the Beat AML clinical trial

新诊断急性髓系白血病60岁及以上患者的分子特征分析:Beat AML临床试验报告

2025-04-030
OA
IDH2 Mutation Is Associated with Favorable Outcome Among Older Adults with Newly Diagnosed Acute Myeloid Leukemia Treated with Lower-Intensity Therapy

IDH2突变与接受低强度治疗的新诊断急性髓系白血病老年患者的良好预后相关。

BLOOD
IF23.1
2024-11-051
PRE
Outcomes and Survival in Newly Diagnosed, Older, Acute Myeloid Leukemia Patients from the Beat AML Master Trial in the Venetoclax/Azacitidine Age

新诊断、老年急性髓系白血病患者在Venetoclax/阿扎胞苷时代的Beat AML主试验中的结局与生存情况

BLOOD
IF23.1
2024-11-050
PRE
Beat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy

Beat-aml 2024 ELN-对新诊断AML的老年人进行低强度治疗的风险分层

2024-10-102
OAAI
Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates
2023-05-258
OAAI
Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial

Entospletinib联合地西他滨治疗TP53突变或复杂核型的急性髓系白血病: Beat AML Master试验的2期子研究

CANCER
IF5.1
2023-04-207
PRE
Safety, Outcomes, and T-Cell Characteristics in Patients with Relapsed or Refractory MDS or CMML Treated with Atezolizumab in Combination with Guadecitabine
2022-10-127
OA
Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial
2020-10-26111
OAAI